Lifetime economic burden of hemophilia using a nationwide real-world healthcare data
PLOS One · 2025
DOI: 10.1371/journal.pone.0333683 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Joo-Young Byun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Hemophilia A, Cost of Illness, Health Care Costs, Hemophilia B. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Patients with hemophilia require lifelong treatment, but the real-world lifetime economic burden of hemophilia remains unclear. This study aims to estimate the lifetime economic burden of hemophilia using real-world data, accounting for cost variation by disease phase and over time.
Methods
Male patients with hemophilia A (PwHa) or B (PwHb) recorded in South Korea’s Health Insurance Review and Assessment (HIRA) database from 2007 to 2022 were included. Survival was estimated using the rolling extrapolation method. A phase-specific costing approach was applied, distinguishing three phases: before hemophilic arthropathy (BH), after hemophilic arthropathy (AH), and 1 year before death (BD). Transition probabilities from BH to AH were calculated based on incidence rates of hemophilic arthropathy. Phase-specific annual costs were modeled using generalized estimating equations (GEEs), and predicted costs were multiplied by phase-specific probabilities from birth to estimated life expectancy to derive lifetime costs.
Results
Estimated life expectancy for PwHa (n = 2,624) and PwHb (n = 664) in South Korea between 2007−2022 was 76.13 and 77.54 years, respectively. The incidence rate of hemophilic arthropathy was 0.090 cases/person-year [95% confidence interval, 0.084–0.097] for PwHa and 0.080 [0.070–0.092] for PwHb, yielding transition probabilities from BH to AH of 0.086 (PwHa) and 0.077 (PwHb). Mean annual costs were highest in the BD phase, followed by AH and BH phases: PwHa (BH: $11,331; AH: $27,271; BD: $27,985); PwHb (BH: $15,567; AH: $38,659; BD: $55,985). Compared to PwHa, PwHb incurred 1.37 and 1.42 times higher BH and AH costs, respectively (p < 0.05). Estimated lifetime cost was 1.76 times higher for PwHb ($22.25 million) than PwHa ($12.62 million) in hypothetical patients born in 2000.
Conclusions
Hemophilia imposes a substantial economic burden across the lifespan, with PwHb incurring higher lifetime costs than PwHa. These real-world estimates can support more informed resource allocation and planning for hemophilia care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania, United States of America.
- School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
ORCID-Profile: Joo-Young Byun, Mihai Park, Eui-Kyung Lee
Zitieren
APA
Byun, J. Y., Jung, J. H., Jang, S. C., Lim, J., Park, M., & Lee, E. K. (2025). Lifetime economic burden of hemophilia using a nationwide real-world healthcare data. PLOS One. https://doi.org/10.1371/journal.pone.0333683
Vancouver
Byun JY, Jung JH, Jang SC, Lim J, Park M, Lee EK. Lifetime economic burden of hemophilia using a nationwide real-world healthcare data. PLOS One. 2025. doi:10.1371/journal.pone.0333683
BibTeX
@article{Byun2025,
author = {Byun, Joo-Young and Jung, Jae-Hoon and Jang, Suk-Chan and Lim, Jamin and Park, Mihai and Lee, Eui-Kyung},
title = {Lifetime economic burden of hemophilia using a nationwide real-world healthcare data},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0333683}
}
EUVIMED